Medios completed the acquision of Ceban Pharmaceuticals from Bencis Capital for €259m.

Medios, a provider of specialty pharma solutions, completed the acquisition of Ceban Pharmaceuticals, a pharmaceutical compounding platform, from Bencis Capital, a private equity firm, for €259m. “We are very pleased that we have now successfully completed the acquisition of Ceban. This transformative acquisition is an important first step in building the leading European Specialty Pharma platform. In addition to cross-selling opportunities and synergies, particularly in purchasing, Ceban's portfolio enables us to strategically diversify while simultaneously tapping into attractive growth markets," Matthias Gaertner, Medios Chairman.